Lioresal

Chronic Pain, Clonus, severe spinal cord origin Spasticity + 11 more

Treatment

20 Active Studies for Lioresal

What is Lioresal

Baclofen

The Generic name of this drug

Treatment Summary

Baclofen is a muscle relaxer that is used to relieve painful or uncomfortable muscle spasms caused by certain medical conditions. It is often prescribed to people with spinal cord injuries to reduce muscle spasticity. There is currently not enough evidence to determine whether baclofen is effective in treating alcohol withdrawal. This drug was approved by the FDA in 1992.

Lioresal

is the brand name

image of different drug pills on a surface

Lioresal Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lioresal

Baclofen

1977

325

Effectiveness

How Lioresal Affects Patients

Baclofen is a drug that helps with muscle relaxation. It works by decreasing the amount of excitatory signals sent from pre-synaptic neurons and increasing the amount of inhibitory signals sent from post-synaptic neurons. Most commonly, it is taken orally. In one study, it was found to be more effective at reducing spasticity when given directly into the spinal cord than when taken orally. Baclofen can cause drowsiness, poor balance, slow breathing, and a decrease in heart rate. It also can help reduce pain and increase stomach acid production. Additionally, baclofen has anti-inflammatory

How Lioresal works in the body

Baclofen works by blocking signals between the brain and muscles. It binds to GABA receptors, which are found on both pre- and post-synaptic neurons. This blocks the action potentials which would normally be sent to the muscles, leading to relaxation of spasticity. It also causes an influx of potassium into the neuron, which further helps to relax the muscles. Baclofen may also act on some voltage-gated calcium channels, but the clinical significance of this is still unclear.

When to interrupt dosage

The measure of Lioresal is contingent upon the identified affliction, including Spasticity, Multiple Sclerosis and Joint Pain. The dosage is subject to the method of delivery (e.g. Injection - Intrathecal or Tablet - Oral) referenced in the table below.

Condition

Dosage

Administration

Muscle Spasticity

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Spinal Cord Diseases

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Multiple Sclerosis

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Clonus

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

severe spinal cord origin Spasticity

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

severe cerebral origin Spasticity

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Muscle Spasticity

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Spinal Cord Injury

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Cerebral Palsy

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Concussion

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Spasm

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Alcoholism

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Muscle Rigidity

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Chronic Pain

10.0 mg, 20.0 mg, , 0.05 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 4.0 mg/mL, 10.0 mg/mL, 25.0 mg, 5.0 mg, 1.0 mg/mg, 3.0 mg/mg, 5.0 mg/mL

Tablet, Tablet - Oral, Kit - Topical, Solution - Intrathecal, , Oral, Kit, Topical, Injection, Intrathecal, Injection - Intrathecal, Injection, solution, Injection, solution - Intrathecal, Cream - Topical, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution - Oral, Solution, Suspension, Suspension - Oral, Granule - Oral, Granule

Warnings

Lioresal Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Baclofen may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Lioresal.

Common Lioresal Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Baclofen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Ethanol

Major

Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Baclofen is combined with Oliceridine.

Thalidomide

Major

Baclofen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

1,2-Benzodiazepine

Minor

Baclofen may increase the central nervous system depressant (CNS depressant) activities of 1,2-Benzodiazepine.

Lioresal Toxicity & Overdose Risk

The lowest toxic dose of baclofen in rats is 145 mg/kg. Symptoms of a baclofen overdose may include confusion, sleepiness, low body temperature, shallow or slow breathing, coma, and seizures. Other rare symptoms can include changes in blood pressure, a slow or fast heartbeat, and vomiting. If someone has overdosed on baclofen, immediate medical attention should be sought. If the patient is awake, vomiting should be induced and their stomach contents should be removed. Unconscious patients should not be encouraged to vomit.

image of a doctor in a lab doing drug, clinical research

Lioresal Novel Uses: Which Conditions Have a Clinical Trial Featuring Lioresal?

451 active studies are currently investigating Lioresal's potential to reduce Clonus, Spasm and severe Spasticity of cerebral origin.

Condition

Clinical Trials

Trial Phases

Spinal Cord Injury

70 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 1

Spinal Cord Diseases

11 Actively Recruiting

Not Applicable, Phase 2

Muscle Spasticity

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Concussion

90 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 3, Phase 1, Phase 4

Multiple Sclerosis

116 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Phase 2, Phase 4, Early Phase 1

Cerebral Palsy

1 Actively Recruiting

Not Applicable

Chronic Pain

123 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

severe spinal cord origin Spasticity

0 Actively Recruiting

severe cerebral origin Spasticity

0 Actively Recruiting

Muscle Spasticity

0 Actively Recruiting

Clonus

0 Actively Recruiting

Spasm

0 Actively Recruiting

Muscle Rigidity

0 Actively Recruiting

Lioresal Reviews: What are patients saying about Lioresal?

4.3

Patient Review

4/21/2009

Lioresal for Muscle Spasms caused by a Spinal Disease

At first, I felt really lightheaded and confused after taking this drug. But now, I can't imagine living without it. It's made life so much easier for me.

4

Patient Review

9/23/2008

Lioresal for Muscle Spasms caused by a Spinal Disease

The medicine works quickly, but the effects don't last very long. Sometimes I have to take a few extra doses when my disease is acting up, but that's to be expected.

2.3

Patient Review

4/13/2010

Lioresal for Muscle Spasms caused by a Spinal Disease

I've been taking this medication for a month now and have yet to see any improvements. My doctor said it would help me with my muscle spasms and cramping, but I still experience those issues just as frequently.

2

Patient Review

1/1/2011

Lioresal for Abnormal Movements of Face Muscles and Tongue

I'm still having muscle spasms and my legs are painful to the touch.

1.3

Patient Review

10/19/2012

Lioresal for Muscle Spasms caused by a Spinal Disease

I've been taking this medication for a few years now, and my doctors have told me that it's the best possible option for my MS. However, I haven't seen much relief in either my facial pain or MS-related pain and stiffness.

1

Patient Review

11/4/2012

Lioresal for Muscle Spasms caused by a Spinal Disease

The very first pill caused me to sleep for an entire day, less half an hour. It also caused me to have a seizure. The doctor ordered me to take 10 mg 3x/day, but I only took one and it had these terrible effects on me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lioresal

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Lioresal make you sleepy?

"This medicine can cause symptoms like dizziness, drowsiness, vision problems, or clumsiness in some people. Be sure to know how you'll react before doing anything that could be dangerous if you're not alert, coordinated, and able to see well."

Answered by AI

What class of drug is Lioresal?

"Baclofen is a drug that is used to relax muscles and reduce spasms. It is often prescribed for people who have multiple sclerosis or spinal cord injuries. Baclofen can help to relieve muscle pain, stiffness, and spasms."

Answered by AI

Are baclofen pain killers?

"No, Baclofen is not a pain killer. It is a muscle relaxer that can help with pain caused by muscle spasms, but will not help with other types of pain."

Answered by AI

What is Lioresal used to treat?

"Lioresal is a medication that helps to relieve spasticity of voluntary muscle that is a result of disorders such as multiple sclerosis, other spinal lesions, motor neurone disease, transverse myelitis, andtraumatic partial section of the cord."

Answered by AI

Clinical Trials for Lioresal

Image of Shirley Ryan AbilityLab in Chicago, United States.

Assistive Technologies for ALS

18+
All Sexes
Chicago, IL

Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function or to compare across tools. This project seeks to address this gap by developing a standardized method to objectively assess or compare the functional benefit of these tools on digital independence, i.e., the ability to independently operate computers, phones, and other digital systems, by creating a unique Digital Assessment Interface (DAI). This assessment will be a simulation of online and digital activities that prior work has determined is important to functional daily living in the digital domain. Participants will complete this assessment with various ATs and BCIs, and these scores will be used to create an index, which will be comprised of performance outcomes, clinician-reported outcomes, and patient-reported outcomes. The tool aims to quantify and compare digital task performance across devices and user populations. The primary objective of this study is to develop an index. The index will quantify functional performance of individuals using various ATs and BCIs. The secondary objectives are to extensively evaluate the psychometric properties of the index, such as the validity, responsiveness, reliability, and floor/ceiling effects both globally and across different devices and impairment levels, ensuring that it can reliably measure the impact of an AT or BCI on a user's ability to independently operate digital systems; and to characterize the familiarization and use of specific BCI and AT systems with reference to a normative healthy control population.

Recruiting
Has No Placebo

Shirley Ryan AbilityLab

Neuralink Corp

Image of Cincinnati Urogynecology Associates in Cincinnati, United States.

Nitrous Oxide for Pain During Bladder Botox Injections

18+
Female
Cincinnati, OH

The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure? Researchers will compare a 50:50 nitrous oxide/oxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain. Participants will: * Receive their bladder Botox injection in the office setting * Either use nitrous oxide/oxygen plus standard care during the procedure, or sham mask plus standard care * Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure

Phase 4
Waitlist Available

Cincinnati Urogynecology Associates (+1 Sites)

Image of HealthPartners Neuroscience Center in Saint Paul, United States.

Intranasal Insulin for Spinal Cord Injury

18 - 84
All Sexes
Saint Paul, MN

The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future. This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.

Phase 1
Recruiting

HealthPartners Neuroscience Center

Leah R Hanson, PhD

Have you considered Lioresal clinical trials?

We made a collection of clinical trials featuring Lioresal, we think they might fit your search criteria.
Go to Trials
Image of Institut de réadaptation Gingras-Lindsay-de-Montréal (IRGLM) in Montreal, Canada.

Spinal Stimulation + Gait Training for Spinal Cord Injury

Any Age
All Sexes
Montreal, Canada

Spinal cord injury (SCI) often results in partial or complete loss of movement. In the subacute phase (\< 6 months), the central nervous system shows increased potential for neuroplasticity, making it more responsive to rehabilitation and external stimulation. Standard care in rehabilitation centers relies on activity-based therapy (ABT), which uses intensive, task-specific training to promote recovery. Although ABT can improve mobility, its effects are often limited due to the nature of SCI and the indirect activation of neural circuits. Recent findings suggest that adding transcutaneous spinal cord stimulation (tSCS) to ABT in chronic SCI (\> 12 months) can enhance lower-limb motor recovery. This study will evaluate whether combining tSCS with gait training is safe and feasible in individuals with subacute SCI and whether it improves lower-limb motor outcomes compared with gait training alone. The investigators hypothesize that pairing gait training with tSCS early after injury will be safe and feasible and that tSCS delivered during gait training will augment leg muscle activation and lead to greater functional improvements. The study will also assess the feasibility, safety and tolerability of implementing this combined intervention in a intensive functional rehabilitation setting.

Recruiting
Senior-friendly

Institut de réadaptation Gingras-Lindsay-de-Montréal (IRGLM)

Mitacs

Image of Shirley Ryan AbilityLab in Chicago, United States.

Motivational Interviewing for Spinal Cord Injury

18+
All Sexes
Chicago, IL

The purpose of this multi-site clinical trial is to see whether people with spinal cord injury or disorder (SCI/D) demonstrate higher level of participation in rehabilitation sessions and other outcomes when their therapists are trained in a counseling style called motivational interviewing. We want to answer the following questions: 1. Do inpatients with SCI/D treated by physical therapists (PTs) and occupational therapists (OTs) who receive MI training and coaching demonstrate greater therapy participation compared to those treated by therapists who do not receive MI training and coaching? 2. Do inpatients with SCI/D treated by PTs and OTs who receive MI training and coaching demonstrate greater functional improvement at discharge from inpatient rehabilitation and greater community integration at 6 months after discharge compared to those treated by therapists who do not receive MI training and coaching? 3. What are the potential moderators and mediators of the effect of training and coaching on MI skills on therapy participation? Researchers will compare patient participation level and other outcomes of inpatients with SCI/D treated by PTs and OTs who receive MI training and coaching with those treated by therapists who do not receive MI training and coaching. Therapist participants will: 1. Audio record 2 therapy sessions per week with each enrolled SCI patient participant 2. Half of the therapists will attend a 16-hour training on MI skills and 2 practice therapy session Patient participants will: 1. Consent to audio recording of their therapy sessions 2. Complete one brief survey near the time of their discharge and another survey 6 months later

Recruiting
Has No Placebo

Shirley Ryan AbilityLab (+2 Sites)

Linda Ehrlich-Jones, PhD, RN

Image of The Mind Research Network in Albuquerque, United States.

Carbon Dioxide for Traumatic Brain Injury

18 - 82
All Sexes
Albuquerque, NM

The current study tests whether different exposures to carbon dioxide (CO2) can safely result in the increased movement of proteins from the brain into the blood. The investigators believe that this would be a proxy for the brain clearing waste products more effectively. The current study will use a counter-balanced design, in which individuals with and without a history of traumatic brain injury (TBI) will receive different levels of CO2 (targeted changes of approximately 5 or 10 mmHG in end-tidal CO2) approximately one week apart. The counter-balanced design means that each participant receives a single dose of CO2 at each visit, and different doses of CO2 at each visit. The order in which participants receive the dose is randomized, and the participant will not be informed of the dose.

Recruiting
Has No Placebo

The Mind Research Network

Andrew R Mayer, Phd

Image of University of Illinois at Chicago in Chicago, United States.

Functional Balance Intervention for Multiple Sclerosis

40 - 90
All Sexes
Chicago, IL

The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.

Recruiting
Has No Placebo

University of Illinois at Chicago

Have you considered Lioresal clinical trials?

We made a collection of clinical trials featuring Lioresal, we think they might fit your search criteria.
Go to Trials
Image of Minneapolis VA Health Care System in Minneapolis, United States.

Brain Stimulation + Cognitive Training for TBI

65+
All Sexes
Minneapolis, MN

The goal of this clinical trial is to learn if combining brain stimulation with cognitive training can improve thinking skills in older adults who have had a traumatic brain injury (TBI). The main questions are: * Does transcranial direct current stimulation (tDCS) make cognitive training more effective for improving attention, memory, and decision-making? * Is this type of home-based program feasible and acceptable for older adults with TBI? Researchers will compare two groups: one group will receive active tDCS during cognitive training, and the other group will receive sham (placebo) tDCS during cognitive training. Participants will: * Complete computer-based cognitive training exercises (BrainHQ) to practice attention, memory, and decision-making. * Receive either active or sham tDCS during training sessions. * Complete assessments before and after the program to measure changes in thinking and daily functioning.

Recruiting
Online Trial

Minneapolis VA Health Care System

Have you considered Lioresal clinical trials?

We made a collection of clinical trials featuring Lioresal, we think they might fit your search criteria.
Go to Trials